Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations.

Background: Polymorphisms with decreased enzyme activity of their gene products have been reported in region CYP2C with population variations in haplotype structure.

Aim: To estimate the allelic and genotypic frequencies of variants CYP2C9*2 and CYP2C9*3 and of CYP2C9/CYP2C19 haplotypes in Venezuelan populations.

Subjects And Methods: Six hundred and thirty-four individuals from nine admixed populations (AP) and the Warao indigenous group were studied.

Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America.

Pharmacogenetics and Pharmacogenomics areas are currently emerging fields focused to manage pharmacotherapy that may prevent undertreatment while avoiding associated drug toxicity in patients. Large international differences in the awareness and in the use of pharmacogenomic testing are presumed, but not well assessed to date. In the present study we review the awareness of Latin American scientific community about pharmacogenomic testing and the perceived barriers for their clinical application.

Distribution of CYP2C19*2 and CYP2C19*3 polymorphisms in Venezuelan populations with different admixture.

Background: The conquest and colonization of Venezuela generated very heterogeneous populations as a product of admixture; for this reason, the distribution of polymorphisms of the CYP2C19 gene was studied in various Venezuelan populations.

Methods: Two hundred and eighty-one individuals, from three Venezuelan populations with different admixtures, were genotyped for CYP2C19*2 and CYP2C19*3 polymorphisms. Differences between groups were analysed using a chi-square test of heterogeneity and association of allele frequencies with the level of genetic admixture was performed using a principal component analysis (PCA).

Activity and levels of factor XIII in a Venezuelan admixed population: association with rs5985 (Val35Leu) and STR F13A01 polymorphisms.

Introduction: The single nucleotide polymorphism Val35Leu has been described within the A subunit of gene Factor XIII (FXIII-A) in association with an increase of FXIII activity. In the gene's promoter region STR F13A01 is present, however there is no available data related about its influence on the expression of FXIII.

Materials And Methods: Blood samples were obtained from apparently healthy and unrelated biologically individuals from northeastern area of Venezuela.